|
1
|
Macdonald DR: Temozolomide for recurrent
high-grade glioma. Semin Oncol. 28 4 Suppl 13:S3–S12. 2001.
View Article : Google Scholar
|
|
2
|
Yung WK: Temozolomide in malignant
gliomas. Semin Oncol. 27 3 Suppl 6:S27–S34. 2000.
|
|
3
|
Wang T, Pickard AJ and Gallo JM: Histone
methylation by temozolomide; a classic DNA methylating anticancer
drug. Anticancer Res. 36:3289–3299. 2016.PubMed/NCBI
|
|
4
|
Roos WP, Batista LF, Naumann SC, Wick W,
Weller M, Menck CF and Kaina B: Apoptosis in malignant glioma cells
triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Villano JL, Seery TE and Bressler LR:
Temozolomide in malignant gliomas: Current use and future targets.
Cancer Chemother Pharmacol. 64:647–655. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Le Rhun E, Taillibert S and Chamberlain
MC: Anaplastic glioma: Current treatment and management. Expert Rev
Neurother. 15:601–620. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nayak L, Panageas KS, Reiner AS, Huse JT,
Pentsova E, Braunthal SG, Abrey LE, DeAngelis LM and Lassman AB:
Radiotherapy and temozolomide for anaplastic astrocytic gliomas. J
Neurooncol. 123:129–134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taal W, Bromberg JE and van den Bent MJ:
Chemotherapy in glioma. CNS Oncol. 4:179–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Momota H, Narita Y, Miyakita Y and Shibui
S: Secondary hematological malignancies associated with
temozolomide in patients with glioma. Neuro Oncol. 15:1445–1450.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Björkholm M, Hultcrantz M and Derolf ÅR:
Leukemic transformation in myeloproliferative neoplasms:
Therapy-related or unrelated. Best Pract Res Clin Haematol.
27:141–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishikawa M, Nakayama K, Rahman MT, Rahman
M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Nakayama N and
Miyazaki K: Therapy-related myelodysplastic syndrome and acute
myeloid leukemia following chemotherapy (paclitaxel and
carboplatin) and radiation therapy in ovarian cancer: A case
report. Eur J Gynaecol Oncol. 35:443–448. 2014.PubMed/NCBI
|
|
12
|
Hamano A, Shingaki S, Abe Y, Miyazaki K,
Sekine R, Nakagawa Y, Tsukada N, Hattori Y and Suzuki K: Impacts of
new agents for multiple myeloma on development of secondary
myelodysplastic syndrome and acute myeloid leukemia. Rinsho
Ketsueki. 55:428–435. 2014.(In Japanese). PubMed/NCBI
|
|
13
|
De Vita S, De Matteis S, Laurenti L,
Chiusolo P, Reddiconto G, Fiorini A, Leone G and Sica S: Secondary
Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol.
84:760–762. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chou KN, Lin YC, Liu MY and Chang PY:
Temozolomide-related acute lymphoblastic leukemia with
translocation (4;11)(q21;q23) in a glioblastoma patient. J Clin
Neurosci. 21:701–704. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shaikh AJ and Masood N: Acute
lymphoblastic leukemia subsequent to temozolomide use in a
26-year-old man: A case report. J Med Case Rep. 4:2742010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ogura M, Todo T, Tanaka M, Nannya Y,
Ichikawa M, Nakamura F and Kurokawa M: Temozolomide may induce
therapy-related acute lymphoblastic leukaemia. Br J Haematol.
154:663–665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Momota H, Narita Y, Miyakita Y, Hosono A,
Makimoto A and Shibui S: Acute lymphoblastic leukemia after
temozolomide treatment for anaplastic astrocytoma in a child with a
germline TP53 mutation. Pediatr Blood Cancer. 55:577–579. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Prevost C, Ferrandi D, Corsetti MT,
Mascolo M, Depaoli L, Salvi F, Bottaro R, Melato M, Palermo M and
Ruiz L: p17.72acute lymphoblastic leukemia after temozolomide
treatment for oligodendroglioma: Case report. Neuro Oncol. 16 Suppl
2:ii1042014. View Article : Google Scholar
|
|
19
|
Kiviniemi A, Gardberg M, Frantzén J,
Parkkola R, Vuorinen V, Pesola M and Minn H: Serum levels of GFAP
and EGFR in primary and recurrent high-grade gliomas: Correlation
to tumor volume, molecular markers, and progression-free survival.
J Neurooncol. 124:237–245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alvarnas JC, Brown PA, Aoun P, Ballen KK,
Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE, et
al: acute lymphoblastic leukemia, Version 2.2015. J Natl Compr Canc
Netw. 13:1240–1279. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Villano JL, Letarte N, Yu JM, Abdur S and
Bressler LR: Hematologic adverse events associated with
temozolomide. Cancer Chemother Pharmacol. 69:107–113. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Scaringi C, De Sanctis V, Minniti G and
Enrici RM: Temozolomide-related hematologic toxicity. Onkologie.
36:444–449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su YW, Chang MC, Chiang MF and Hsieh RK:
Treatment-related myelodysplastic syndrome after temozolomide for
recurrent high-grade glioma. J Neurooncol. 71:315–318. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim SJ, Park TS, Lee ST, Song J, Suh B,
Kim SH, Jang SJ, Lee CH and Choi JR: Therapy-related
myelodysplastic syndrome/acute myeloid leukemia after treatment
with temozolomide in a patient with glioblastoma multiforme. Ann
Clin Lab Sci. 39:392–398. 2009.PubMed/NCBI
|
|
26
|
Chamberlain MC and Raizer J: Extended
exposure to alkylator chemotherapy: Delayed appearance of
myelodysplasia. J Neurooncol. 93:229–232. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mauritzson N, Albin M, Rylander L,
Billström R, Ahlgren T, Mikoczy Z, Björk J, Strömberg U, Nilsson
PG, Mitelman F, et al: Pooled analysis of clinical and cytogenetic
features in treatment-related and de novo adult acute myeloid
leukemia and myelodysplastic syndromes based on a consecutive
series of 761 patients analyzed 1976–1993 and on 5098 unselected
cases reported in the literature 1974–2001. Leukemia. 16:2366–2378.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pagano L, Pulsoni A, Tosti ME, Annino L,
Mele A, Camera A, Martino B, Guglielmi C, Cerri R, Di BE, et al:
Acute lymphoblastic leukaemia occurring as second malignancy:
Report of the GIMEMA archive of adult acute leukaemia. Gruppo
Italiano Malattie Ematologiche Maligne dell' Adulto. Br J Haematol.
106:1037–1040. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hunger SP, Sklar J and Link MP: Acute
lymphoblastic leukemia occurring as a second malignant neoplasm in
childhood: Report of three cases and review of the literature. J
Clin Oncol. 10:156–163. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Geiger H, Schleimer D, Nattamai KJ,
Dannenmann SR, Davies SM and Weiss BD: Mutagenic potential of
temozolomide in bone marrow cells in vivo. Blood. 107:3010–3011.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Alam N, Atenafu EG, Kuruvilla J, Uhm J,
Lipton JH, Messner HA, Kim DH, Seftel M and Gupta V: Outcomes of
patients with therapy-related AML/myelodysplastic syndrome
(t-AML/MDS) following hematopoietic cell transplantation. Bone
Marrow Transplant. 50:1180–1186. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aldoss I, Dagis A, Palmer J, Forman S and
Pullarkat V: Therapy-related ALL: Cytogenetic features and
hematopoietic cell transplantation outcome. Bone Marrow Transplant.
50:746–748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferrero D, Crisà E, Marmont F, Audisio E,
Frairia C, Giai V, Gatti T, Festuccia M, Bruno B, Riera L, et al:
Survival improvement of poor-prognosis AML/MDS patients by
maintenance treatment with low-dose chemotherapy and
differentiating agents. Ann Hematol. 93:1391–1400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Perry JR, Brown MT and Gockerman JP: Acute
leukemia following treatment of malignant glioma. J Neurooncol.
40:39–46. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pagano L, Pulsoni A, Tosti ME, Avvisati G,
Mele L, Mele M, Martino B, Visani G, Cerri R, Di Bona E, et al:
Clinical and biological features of acute myeloid leukaemia
occurring as second malignancy: GIMEMA archive of adult acute
leukaemia. Br J Haematol. 112:109–117. 2001. View Article : Google Scholar : PubMed/NCBI
|
